patient management

Whole-blood point-of-care glial fibrillary acidic protein and ubiquitin C-terminal hydrolase L1 biomarkers after traumatic brain injury in the US: a prospective diagnostic prediction of intracranial injury on head CT

Study Overview The investigation centers on the utility of two specific biomarkers—glial fibrillary acidic protein (GFAP) and ubiquitin C-terminal hydrolase […]

Whole-blood point-of-care glial fibrillary acidic protein and ubiquitin C-terminal hydrolase L1 biomarkers after traumatic brain injury in the US: a prospective diagnostic prediction of intracranial injury on head CT Read Post »

Analysis of the Use of Duloxetine in the High-dose Range (90 to 120 mg) in the Psychiatric Clinic for the Treatment of Patients With Major Depressive Disorder

Analysis of the Use of Duloxetine in the High-dose Range (90 to 120 mg) in the Psychiatric Clinic for the Treatment of Patients With Major Depressive Disorder

Duloxetine Efficacy in High Doses Duloxetine, a selective serotonin and norepinephrine reuptake inhibitor, has been widely studied for its effectiveness

Analysis of the Use of Duloxetine in the High-dose Range (90 to 120 mg) in the Psychiatric Clinic for the Treatment of Patients With Major Depressive Disorder Read Post »

Correction to “Interpreting the Hospital Anxiety and Depression Scale (HADS) for individuals with traumatic brain injury: Clinical correlates and empirical severity cutoffs” by Fox et al. (2026)

Study Overview This study, conducted by Fox et al. (2026), addresses the significance of the Hospital Anxiety and Depression Scale

Correction to “Interpreting the Hospital Anxiety and Depression Scale (HADS) for individuals with traumatic brain injury: Clinical correlates and empirical severity cutoffs” by Fox et al. (2026) Read Post »

Scroll to Top